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Home mechanical ventilation in chest wall disease
should aim at full correction of PaCO2Patients with chronic respiratory failure due to chest wall
disease are likely to live longer if they receive home
mechanical ventilation (HMV), though the evidence is mainly
indirect.1,2 The most frequently cited guidelines3 are very
vague on technical procedures and primary therapeutic aims.
The recently published HMV guidelines (in German) from the
German Society of Pneumology4 are much more elaborate.
The Society’s recommendation for COPD is that treatment
should aim at full correction of PaCO2 on spontaneous
breathing.However, the statement seems tobe foundedmore
on consensus than strong evidence, and for patients with
chest wall disease, the German guidelines are less precise.
In this issue of Respiratory Medicine, a group from Bar-
celona presents important data on the predictors of survival
in patients with chest wall disease (scoliosis or tuberculosis
sequelae) who receive HMV.5 The group’s main conclusion is
that patients who achieve normal or close to normal PaCO2
(<50 mm Hg) during daytime spontaneous breathing one
month after the initiation of HMV have significantly better
survival outcomes. On a superficial level, this conclusion
may appear as rather self-evident. However, few previous
studies have addressed the question of how ambitious one
should be in attempts to normalise blood gases.
A Japanese study on patients with tuberculosis sequelae,
which is also published in this issue, demonstrates a “dose-
response” relationship between PaCO2 levels obtained after
3e6 months and survival with HMV.6 The Japanese group
defined patients with a PaCO2 < 60 mm Hg as their best
responders, which is a very modest ambition in my opinion.
In that study, many patients seemed to not respond
adequately to the treatment. The applied pressures were
comparatively low and they were slightly higher in the
study from Barcelona (Pallero, personal communication).
The Japanese patients may also have been less compliant
with the therapy than the Barcelona patients in terms of
usage hours (Tsuboi, personal communication). Neverthe-
less, the survival benefits for the group with the lowest
PaCO2 were evident.DOI of original articles: 10.1016/j.rmed.2010.08.013, 10.1016/
j.rmed.2010.04.027
0954-6111/$ - see front matter ª 2010 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2010.08.014In addition, there may be more to this than just blood gas
physiology. Olofson et al. have shown that preserved or
improved global quality of life after 9 months of HMV
treatment was related to better long-term survival.7 Quality
of life may improve early after instituting HMV, provided
that the therapy is aggressive enough to normalise daytime
blood gases.8 To achieve this goal, ventilator settings have to
be carefully monitored and adjusted.9,10
There may of course be other identified or not yet iden-
tified confounding factors, such as comorbidity.5 Undernu-
trition and a more advanced disease state may have been
present in the Japanese study. Patient factors may deter-
mine the subdivision into responders and non-responders in
terms of blood gases and quality of life, which is largely
independent of the technical efforts of the caregiver, and
such patient factors may be relevant for survival.
My interpretation of the data provided in this issue of
Respiratory Medicine is that an active approach should be
applied. Therapy should bemonitored and adjusted with full
correction of the blood gases during spontaneous breathing
as the primary aim. If this approach seems to faile try a little
harder! The data from Olofson et al.7 and Windisch8 suggest
that there is no conflict between this goal and improvement
in quality of life. In many instances, refining the therapy,
such as asynchrony correction11 or increasing volume or
pressure,10 will result in improved ventilation and ultimately
in better daytime blood gases and quality of life. The data
from Barcelona and from Japan published in this issue of
Respiratory Medicine5,6 encourage us to refine our HMV
therapy with respect to survival.
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